{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=31&q=small+cell+lung+cancer", "query": { "q": "small cell lung cancer", "condition": "Lung Cancer", "page": 31 }, "page_size": 10 }, "pagination": { "page": 31, "page_size": 10, "total_count": 4379, "total_pages": 438, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=32&q=small+cell+lung+cancer&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=30&q=small+cell+lung+cancer&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T15:19:34.094Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05035407", "title": "T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kita-kyushu Lung Cancer Antigen 1, Human" ], "interventions": [ { "name": "IL-2 (Aldesleukin)", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "KK-LC-1 TCR", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "CXR", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "PET", "type": "DIAGNOSTIC_TEST" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Meperidine", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 36, "start_date": "2022-03-08", "completion_date": "2025-07-16", "has_results": true, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-10-16T15:19:34.094Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05035407" }, { "nct_id": "NCT03574753", "title": "Lung-MAP S1400K: c-MET Positive", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma AJCC V7" ], "interventions": [ { "name": "ABBV-399", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2018-03-16", "completion_date": "2021-07-30", "has_results": true, "last_update_posted_date": "2021-10-18", "last_synced_at": "2026-10-16T15:19:34.094Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03574753" }, { "nct_id": "NCT04101357", "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Extensive-stage Small Cell Lung Cancer" ], "interventions": [ { "name": "BNT411", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2020-06-19", "completion_date": "2024-05-23", "has_results": true, "last_update_posted_date": "2025-03-18", "last_synced_at": "2026-10-16T15:19:34.094Z", "location_count": 3, "location_summary": "Los Angeles, California • Chicago, Illinois • Greenville, South Carolina", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04101357" }, { "nct_id": "NCT01750281", "title": "Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV" ], "interventions": [ { "name": "Selumetinib 75 mg", "type": "DRUG" }, { "name": "Docetaxel 75 mg/m2", "type": "DRUG" }, { "name": "Docetaxel 60 mg/m2", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 212, "start_date": "2012-12-18", "completion_date": "2022-10-31", "has_results": true, "last_update_posted_date": "2023-10-24", "last_synced_at": "2026-10-16T15:19:34.094Z", "location_count": 13, "location_summary": "Santa Monica, California • Aurora, Colorado • Hollywood, Florida + 9 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01750281" }, { "nct_id": "NCT07124000", "title": "DESTINY-PANTUMOUR04", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma (NOS)", "Anal Cancer", "Bladder Cancer", "Cervical Cancer", "Endometrial Cancer", "Esophageal Cancer", "Gall Bladder Cancer", "Gastrointestinal Stromal Tumour", "Head and Neck Cancer", "Liver Cancer", "Melanoma", "Mouth Cancer", "Nasopharangeal Cancer", "Neuroendocrine, Gastrointestinal Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Renal Cell Carcinoma", "Salivary Gland Cancer", "Sarcoma", "Small Cell Lung Cancer", "Testicular Cancer", "Throat Cancer", "Thyroid Cancer", "Urethral Cancer", "Vaginal Cancer", "Vulvar Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 100, "start_date": "2025-09-18", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-16T15:19:34.094Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bullhead City", "state": "Arizona" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07124000" }, { "nct_id": "NCT03786692", "title": "Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Carcinoma of Lung, TNM Stage 4" ], "interventions": [ { "name": "Arm A", "type": "DRUG" }, { "name": "Arm B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2019-09-04", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-16T15:19:34.094Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03786692" }, { "nct_id": "NCT06403436", "title": "A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Adult Solid Tumor", "Adult Disease", "Cancer", "NSCLC", "EGFR", "KRAS G12C", "Squamous Cell Lung Cancer" ], "interventions": [ { "name": "TT125-802", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TOLREMO therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2023-11-07", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-16T15:19:34.094Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Fairfax, Virginia", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06403436" }, { "nct_id": "NCT00856037", "title": "Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 22, "start_date": "2009-02-02", "completion_date": "2018-02-01", "has_results": false, "last_update_posted_date": "2023-09-26", "last_synced_at": "2026-10-16T15:19:34.094Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00856037" }, { "nct_id": "NCT04933695", "title": "A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Sotorasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2022-01-28", "completion_date": "2025-05-28", "has_results": true, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-16T15:19:34.094Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Duarte, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04933695" }, { "nct_id": "NCT03382912", "title": "Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Pegilodecakin", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2018-03-22", "completion_date": "2020-03-03", "has_results": true, "last_update_posted_date": "2020-09-11", "last_synced_at": "2026-10-16T15:19:34.094Z", "location_count": 35, "location_summary": "Tempe, Arizona • Beverly Hills, California • Los Angeles, California + 30 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03382912" } ] }